Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH

Genes Chromosomes and Cancer

Volumn 46, Issue 6, 2007, Pages 532-542

  Lai, Lisa A ^a   Paulson, Thomas G ^b   Li, Xiaohong ^b   Sanchez, Carissa A ^b   Maley, Carlo ^c   Odze, Robert D ^d   Reid, Brian J ^a,b   Rabinovitch, Peter S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c WISTAR INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANEUPLOIDY; ARTICLE; BARRETT ESOPHAGUS; CANCER GENETICS; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CDKN2A GENE; CELL TRANSFORMATION; CHROMOSOMAL INSTABILITY; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; GENE NUMBER; GENETIC ASSOCIATION; GENETIC RECOMBINATION; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; MOLECULAR CLONING; PRECANCER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

BARRETT ESOPHAGUS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; EVOLUTION, MOLECULAR; GENE DOSAGE; GENOMIC INSTABILITY; HUMANS; LONGITUDINAL STUDIES; LOSS OF HETEROZYGOSITY; NEOPLASMS; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECANCEROUS CONDITIONS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247476112     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20435     Document Type: Article

References (44)

1. Adams J, Williams SV, Aveyard JS, Knowles MA. 2005. Loss of heterozygosity analysis and DNA copy number measurement on 8p in bladder cancer reveals two mechanisms of allelic loss. Cancer Res 65:66-75.
2. Albrecht B, Hausmann M, Zitzelsberger H, Stein H, Siewert JR, Hopt U, Langer R, Hofler H, Werner M, Walch A. 2004. Array-based comparative genomic hybridization for the detection of DNA sequence copy number changes in Barrett's adenocarcinoma. J Pathol 203:780-788.
3. Bignell GR, Huang J, Greshock J, Watt S, Butler A, West S, Grigorova M, Jones KW, Wei W, Stratton MR, Futreal PA, Weber B, Shapero MH, Wooster R. 2004. High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res 14:287-295.
4. Croft J, Parry EM, Jenkins GJ, Doak SH, Baxter JN, Griffiths AP, Brown TH, Parry JM. 2002. Analysis of the premalignant stages of Barrett's oesophagus through to adenocarcinoma by comparative genomic hybridization. Eur J Gastroenterol Hepatol 14:1179-1186.
5. de Nooij-van Dalen AG, Giphart MJ, Lohman PH. Giphart-Gassler M. 1999. Both the rate and spectrum of loss of heterozygosity differ between human lymphoblastoid cells derived from various donors. Mutat Res 423:1-10.
6. Dolan K, Walker SJ, Gosney J, Field JK, Sutton R. 2003. TTP53 mutations in malignant and premalignant Barrett's esophagus. Dis Esophagus 16:83-89.
7. Gaasenbeek M, Howarth K, Rowan AJ, Gorman PA, Jones A, Chaplin T, Liu Y, Bicknell D, Davison EJ, Fiegler H, Carter NP, Roylance RR, Tomlinson IP. 2006. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancers. Cancer Res 66:3471-3479.
8. Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Levine DS, Rabinovitch PS, Reid BJ. 1996. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci USA 93:7081-7084.
9. Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, Reid BJ. 1999. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst 91:2087-2095.
10. Gonzalez MV, Artimez ML, Rodrigo L, Lopez-Larrea C, Menendez MJ, Alvarez V, Perez R, Fresno MF, Perez MJ, Sampedro A, Coto E. 1997. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol 50:212-217.
11. Hage M, Siersema PD, Vissers KJ, Dinjens WN, Steyerberg EW, Haringsma J, Kuipers EJ, van Dekken H. 2006. Genomic analysis of Barrett's esophagus after ablative therapy: Persistence of genetic alterations at tumor suppressor loci. Int J Cancer 118:155-160.
12. Hardie LJ, Darnton SJ, Wallis YL, Chauhan A, Hainaut P, Wild CP, Casson AG. 2005. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett 217:221-230.
13. Huang J, Wei W, Zhang J, Liu G, Bignell GR, Stratton MR, Futreal PA, Wooster R, Jones KW, Shapero MH. 2004. Whole genome DNA copy number changes identified by high density oligonucleotide arrays. Hum Genomics 1:287-299.
14. Jenkins GJ, D'Souza FR, Suzen HS, Eltahir ZS, James SA, Parry JM, Griffiths AP, Baxter JN. 2007. Deoxycholic acid (DCA) at neutral and acid pH, is genotoxic to oesophageal cells through the induction of ROS: The potential role of antioxidants in Barrett's oesophagus. Carcinogenesis 28:136-142.
15. Koppert LB, Wijnhoven BP, van Dekken H, Tilanus HW, Dinjens WN. 2005. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 92:169-190.
16. Lasko D, Cavenee W, Nordenskjold M. 1991. Loss of constitutional heterozygosity in human cancer. Annu Rev Genet 25:281-314.
17. Lee JS, Oh TY,'Ahn BO, Cho H, Kim WB, Kim YB, Surh YJ, Kim HJ, Hahm KB. 2001. Involvement of oxidative stress in experimentally induced reflux esophagitis and Barrett's esophagus: Clue for the chemoprevention of esophageal carcinoma by antioxidants. Mutat Res 480/481:189-200.
18. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. 2004. dChipSNP: Significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 20:1233-1240.
19. Lisitsyn NA, Lisitsina NM, Dalbagni G, Barker P, Sanchez CA, Gnarra J, Linehan WM, Reid BJ, Wigler MH. 1995. Comparative genomic analysis of tumors: Detection of DNA losses and amplification. Proc Natl Acad Sci USA 92:151-155.
20. Loeb LA. 1991. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51:3075-3079.
21. Loo LW, Grove DI, Williams EM, Neal CL, Cousens LA, Schubert EL, Holcomb IN, Massa HF, Glogovac J, Li CI, Malone KE, Daling JR, Delrow JJ, Trask BJ, Hsu L, Porter PL. 2004. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 64:8541-8549.
22. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques RA, Rabinovitch PS, Reid BJ. 2006. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 38:468-473.
23. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Blount PL, Reid BJ. 2004a. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 64:7629-7633.
24. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ. 2004b. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 64:3414-3427.
25. Michael D, Beer DG, Wilke CW, Miller DE, Glover TW. 1997. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas. Oncogene 15:1653-1659.
26. Nowell PC. 1991. Genetic instability and tumor development. Basic Life Sci 57:221-228; discussion 228-231.
27. Paulson TG, Galipeau PC, Reid BJ. 1999. Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res 9:482-491.
28. Payne CM, Weber C, Crowley-Skillicorn C, Dvorak K, Bernstein H, Bernstein C, Holubec H, Dvorakova B, Garewal H. 2007. Deoxycholate induces mitochondrial oxidative stress and activates NF-κB through multiple mechanisms in HCT-116 colon epithelial cells. Carcinogenesis 28:215-222.
29. Pinkel D, Albertson DG. 2005. Comparative genomic hybridization. Annu Rev Genomics Hum Genet 6:331-354.
30. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. 2001. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 96:3071-3083.
31. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. 1992. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort. Gastroenterology 102:1212-1219.
32. Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, Blount PL, Rabinovitch PS. 2001. Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 96:2839-2848.
33. Sanz-Ortega J, Hernandez S, Saez MC, Sierra E, Sanz-Ortega G, Torres A, Balibrea JL, Sanz-Esponera J, Merino MJ. 2003. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia. Hepatogastroenterology 50:404-407.
34. Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y, Olaru A, Wang S, Mori Y, Deacu E, Hamilton JP, Kan T, Abraham JM, Schmiegel W, Harpaz N, Meltzer SJ. 2005. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 24:4138-4148.
35. Sihvo EI, Salminen JT, Rantanen TK, Ramo OJ, Ahotupa M, Farkkila M, Auvinen MI, Salo JA. 2002. Oxidative stress has a role in malignant transformation in Barrett's oesophagus. Int J Cancer 102:551-555.
36. Teh MT, Blaydon D, Chaplin T, Foot NJ, Skoulakis S, Raghavan M, Harwood CA, Proby CM, Philpott MP, Young BD, Kelsell DP. 2005. Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res 65:8597-8603.
37. Turker MS, Gage BM, Rose JA, Elroy D, Ponomareva ON, Stambrook PJ, Tischfield JA. 1999. A novel signature mutation for oxidative damage resembles a mutational pattern found commonly in human cancers. Cancer Res 59:1837-1839.
38. Wang P, Kim Y, Pollack J, Narasimhan B, Tibshirani R. 2005. A method for calling gains and losses in array CGH data. Biostatistics 6:45-58.
39. Wang YH. 2006. Chromatin structure of human chromosomal fragile sites. Cancer Lett 232:70-78.
40. Wild CP, Hardie LJ. 2003. Reflux, Barrett's oesophagus and adenocarcinoma: Burning questions. Nat Rev Cancer 3:676-684.
41. Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, Reid BJ. 2001. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 61:8284-8289.
42. Wongsurawat VJ, Finley JC, Galipeau PC, Sanchez CA, Maley CC, Li X, Blount PL, Odze RD, Rabinovitch PS, Reid BJ. 2006. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: Implications for biomarker validation. Cancer Epidemiol Biomark Prev 15:509-516.
43. Yano S, Matsuyama H, Matsuda K, Matsumoto H, Yoshihiro S, Naito K. 2004. Accuracy of an array comparative genomic hybridization (CGH) technique in detecting DNA copy number aberrations: Comparison with conventional CGH and loss of heterozygosity analysis in prostate cancer. Cancer Genet Cytogenet 150:122-127.
44. Zhou X, Mok SC, Chen Z, Li Y, Wong DT. 2004. Concurrent analysis of loss of heterozygosity (LOH) and copy number abnormality (CNA) for oral premalignancy progression using the Affymetrix 10K SNP mapping array. Hum Genet 115:327-330.